Conditions: Refractory Cutaneous T-cell Lymphoma
Keywords: CTCL bexarotene Targretin Refractory Cutaneous T-cell Lymphoma cutaneous T-cell Lymphoma MF Mycoses fungoides
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 59
Healthy volunteers: no

Brief summary:
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.

Detailed description:

Arms:
arm 1: Participants will receive bexarotene 150 mg/m\^2/day once daily for 24 weeks. arm 2: Participants will receive bexarotene 300 mg/m\^2/day once daily for 24 weeks.

Interventions: intervention 1: Bexarotene
Intervention descriptions: intervention 1: Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.

Protocol document: